Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

5.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.0K
Varicose Veins II: Diagnostic Studies and Interprofessional Care01:26

Varicose Veins II: Diagnostic Studies and Interprofessional Care

56
Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
56
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.2K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

704
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
704
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

256
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
256
Tissue Renewal without Stem Cells01:23

Tissue Renewal without Stem Cells

1.9K
After cellular or tissue damage, the resident stem cells present in the human body can locally repair and regenerate the damaged tissue or organ. However, even though some tissues do not have stem cells, they can repair and regenerate with the help of pre-existing cells. For example, beta cells of the pancreas and hepatocytes of the liver can divide to renew and regenerate the tissue. Here, both cell division and cell death are well regulated by homeostasis.
However, failure of such a system...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial transcriptomics identifies immune-stromal niches associated with cancer in adult dermatomyositis.

Nature communications·2026
Same author

A spatially coordinated keratinocyte-fibroblast circuit recruits MMP9<sup>+</sup> myeloid cells to drive type I interferon-driven inflammation in photosensitive autoimmunity.

Nature immunology·2026
Same author

Leveraging tissue-resident memory T cells for non-invasive immune monitoring via microneedle skin patches.

Nature biomedical engineering·2026
Same author

A Spatially Coordinated Keratinocyte-Fibroblast Circuit Recruits MMP9<sup>+</sup> Myeloid Cells to Drive IFN-I-Driven Inflammation in Photosensitive Autoimmunity.

bioRxiv : the preprint server for biology·2025
Same author

Endothelial Cell Expression of STING <sup>V154M</sup> Gain-of-Function Mutation Delays the Resolution of UVB-induced Skin Injury.

bioRxiv : the preprint server for biology·2025
Same author

Leveraging tissue-resident memory T cells for non-invasive immune monitoring via microneedle skin patches.

medRxiv : the preprint server for health sciences·2025

Related Experiment Video

Updated: Oct 28, 2025

Author Spotlight: Non-Surgical Treatment of Melasma&#8211; Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.2K

Upcoming treatments for morphea.

Dan Wenzel1, Nazgol-Sadat Haddadi1, Khashayar Afshari1

  • 1Department of Dermatology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

Immunity, Inflammation and Disease
|July 17, 2021
PubMed
Summary

Morphea, a rare autoimmune skin disease, affects children more often and has distinct features from systemic sclerosis. This review explores promising new therapies targeting its complex causes.

Keywords:
clinical triallocalized sclerodermamorpheatreatment

More Related Videos

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
07:36

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

308
Using a 1064-nm Picosecond Neodymium-Doped Yttrium Aluminum Garnet Laser for Periorbital Hyperpigmentation
04:43

Using a 1064-nm Picosecond Neodymium-Doped Yttrium Aluminum Garnet Laser for Periorbital Hyperpigmentation

Published on: May 23, 2025

433

Related Experiment Videos

Last Updated: Oct 28, 2025

Author Spotlight: Non-Surgical Treatment of Melasma&#8211; Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.2K
Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
07:36

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

308
Using a 1064-nm Picosecond Neodymium-Doped Yttrium Aluminum Garnet Laser for Periorbital Hyperpigmentation
04:43

Using a 1064-nm Picosecond Neodymium-Doped Yttrium Aluminum Garnet Laser for Periorbital Hyperpigmentation

Published on: May 23, 2025

433

Area of Science:

  • Dermatology
  • Rheumatology
  • Immunology

Background:

  • Morphea, a rare autoimmune connective tissue disease, presents variably with an incidence of 0.4-2.7 per 100,000.
  • It predominantly affects children (2-14 years) and shows a female bias.
  • While sharing some histopathology with systemic sclerosis, morphea is clinically distinct.

Purpose of the Study:

  • To review emerging therapeutic strategies for morphea.
  • To discuss novel treatments based on preclinical data and clinical trials.
  • To highlight how new therapies address morphea's complex pathogenesis.

Main Methods:

  • Review of preclinical evidence for novel morphea therapies.
  • Analysis of ongoing clinical trials for morphea treatments.
  • Focus on therapeutic classes targeting disease mechanisms.

Main Results:

  • Identification of antifibrotic, anti-inflammatory, cellular, gene, and antisenolytic therapies.
  • Preclinical and clinical data support these novel approaches.
  • Therapies are categorized by their targeted pathogenic pathways.

Conclusions:

  • New therapeutic avenues for morphea are emerging.
  • These treatments target diverse aspects of morphea pathogenesis, including fibrosis and inflammation.
  • Further research and clinical trials are crucial for advancing morphea treatment.